532978 Sigma-AldrichPLD2 Inhibitor, ML395 - CAS 1638957-17-1 - Calbiochem
ML395 is a cell permeable, highly potent, selective, and direct allosteric inhibitor of phospholipase D2 (PLD2; IC₅₀ = 360 nM) that exhibits >80-fold selectivity over PLD1.
More>> ML395 is a cell permeable, highly potent, selective, and direct allosteric inhibitor of phospholipase D2 (PLD2; IC₅₀ = 360 nM) that exhibits >80-fold selectivity over PLD1. Less<<Synonyms: Phosppolipase D2 inhibitor, VU0468809, ML-395
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
CAS # | Empirical Formula |
---|---|
1638957-17-1 | C₂₆H₂₉N₅O₂ |
Pricing & Availability
Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.32978.0001 |
|
Glass bottle | 10 mg |
|
— |
References | |
---|---|
References | O'Reilly, M.C., et al. 2014. ChemMedChem 9, 2633. |
Product Information | |
---|---|
CAS number | 1638957-17-1 |
Form | Off-white solid |
Hill Formula | C₂₆H₂₉N₅O₂ |
Chemical formula | C₂₆H₂₉N₅O₂ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | PLD2 |
Primary Target IC<sub>50</sub> | 360 nM |
Purity | ≥97% by HPLC |
Physicochemical Information |
---|
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
5.32978.0001 | 04055977281972 |
Documentation
PLD2 Inhibitor, ML395 - CAS 1638957-17-1 - Calbiochem MSDS
Title |
---|
References
Reference overview |
---|
O'Reilly, M.C., et al. 2014. ChemMedChem 9, 2633. |
Technical Info
Title |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |